Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 5/8/2020
SIETES contiene 93082 citas

 1 a 20 de 60 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Robblee JV, Butterfield RJ, Kang AM, Smith JM. Triptan and ergotamine overdoses in the United States. Analysis of the National Poison Data System. Neurology 2020:1. [Ref.ID 103505]
2.Tiene citas relacionadas Cita con resumen
Anónimo. In brief: oral phenylephrine for nasal congestion. The Medical Letter on Drug and Therapeutics Bulletin 2015;57:174. [Ref.ID 99738]
3. Cita con resumen
Law R, Schier J, Martin C, Chang A, Wolkin A. Notes from the field: Increase in reported adverse health effects related to synthetic cannabinoid use — United States, January–May 2015. MMWR Morb Mortal Wkly Rep 2015;64:618-9. [Ref.ID 99193]
4. Cita con resumen
Anónimo. FDA approves weight-management drug Saxenda. U.S. Food and Drug Administration 2014:23 de diciembre. [Ref.ID 98393]
5. Cita con resumen
Hampton T. FDA alert on pure caffeine powder. JAMA 2014;312:779. [Ref.ID 97897]
6. Cita con resumen
Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ 2014;348:g1626. [Ref.ID 97343]
7. Cita con resumen
Comte H, Auffret M, Lelièvre B, Béné J, Steen P, Gautier S. Tachycardie et douleurs précordiales sous agomélatine: à propos d'un cas. Therapie 2013;68:324-5. [Ref.ID 96645]
8. Cita con resumen
Anónimo. Néfopam: un bilan français. Prescrire 2013;33:825. [Ref.ID 96494]
9. Cita con resumen
Morelli A, Donati A, Ertmer C, Rehberg S, Kampmeier T, Orecchioni A, D'Egidio A, Cecchini V, Landoni G, Pietrapaoli P, Westphal M, Venditti M, Mebazaa A, Singer M. Microvascular effects of heart rate control with esmolol in patients with septic shock: a pilot study. Crit Care Med 2013;41:2162-8. [Ref.ID 95957]
10.Enlace a cita original Cita con resumen
Anónimo. Seguridad de medicamentos: señales y alertas generadas en 2011-2012. Infac: Información Farmacoterapéutica de la Comarca 2013;21:1-9. [Ref.ID 95177]
11. Cita con resumen
Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosenbraugh C. The FDA's assessment of two drugs for chronic weight management. N Engl J Med 2012;367:1577-9. [Ref.ID 93939]
12. Cita con resumen
Anónimo. Mirabegron approved for overactive bladder. United States of America. WHO Drug Information 2012;26:274-5. [Ref.ID 93689]
15. Cita con resumen
Vitalone A, Menniti-Ippolito F, Moro PA, Firenzuoli F, Raschetti R, Mazzanti G. Suspected adverse reactions associated with herbal products used for weight loss: a case series reported to the Italian National Institute of Health. Eur J Clin Pharmacol 2011;67:215-24. [Ref.ID 90094]
16. Cita con resumen
17. Cita con resumen
Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C. Cilostazol for prevention of secondary stroke (CSPS 2): An aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010;9:942-3. [Ref.ID 89402]
Scheen AJ. Controversy about the cardiovascular safety of sibutramine. Drug Saf 2010;33:615-8. [Ref.ID 88757]
20. Cita con resumen
Winstock AR, Ford C, Witton J. Assessment and management of cannabis use disorders in primary care. BMJ 2010;340:800-4. [Ref.ID 88314]
Seleccionar todas
 1 a 20 de 60 siguiente >>